162 related articles for article (PubMed ID: 30061252)
1. A Phase I Study of S-1-based Concurrent Chemoradiotherapy Followed by Gemcitabine and S-1 in Metastatic Pancreatic Adenocarcinoma.
Yang SH; Shao YY; Lin CC; Kuo SH; Cheng AL; Yeh KH
Anticancer Res; 2018 Aug; 38(8):4805-4812. PubMed ID: 30061252
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
Sudo K; Yamaguchi T; Ishihara T; Nakamura K; Hara T; Denda T; Tawada K; Imagumbai T; Araki H; Sakai M; Hatano K; Kawakami H; Uno T; Ito H; Yokosuka O
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):119-25. PubMed ID: 20605363
[TBL] [Abstract][Full Text] [Related]
3. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study.
Chiang NJ; Tsai KK; Hsiao CF; Yang SH; Hsiao HH; Shen WC; Hsu C; Lin YL; Chen JS; Shan YS; Chen LT
Eur J Cancer; 2020 Jan; 124():123-130. PubMed ID: 31765987
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer.
Sudo K; Yamaguchi T; Nakamura K; Denda T; Hara T; Ishihara T; Yokosuka O
Cancer Chemother Pharmacol; 2011 Feb; 67(2):249-54. PubMed ID: 20352216
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604).
Tahara M; Fuse N; Mizusawa J; Sato A; Nihei K; Kanato K; Kato K; Yamazaki K; Muro K; Takaishi H; Boku N; Ohtsu A
Cancer Sci; 2015 Oct; 106(10):1414-20. PubMed ID: 26250827
[TBL] [Abstract][Full Text] [Related]
6. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
Ke QH; Zhou SQ; Yang JY; Du W; Liang G; Lei Y; Luo F
World J Gastroenterol; 2014 Oct; 20(38):13987-92. PubMed ID: 25320537
[TBL] [Abstract][Full Text] [Related]
7. A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Okano K; Suto H; Oshima M; Maeda E; Yamamoto N; Kakinoki K; Kamada H; Masaki T; Takahashi S; Shibata T; Suzuki Y
Ann Surg Oncol; 2017 Sep; 24(9):2777-2784. PubMed ID: 28608121
[TBL] [Abstract][Full Text] [Related]
8. A Phase I Study of S-1 and Gemcitabine with Concurrent Radiotherapy in Patients with Non-Metastatic Advanced Pancreatic Cancer.
Kobayashi S; Honda G; Kurata M; Okuda Y; Sakamoto K; Karasawa K; Chang T; Egawa N; Kamisawa T; Omuro Y; Tsuruta K
Hepatogastroenterology; 2015 Jun; 62(140):1031-6. PubMed ID: 26902051
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and S-1 Induction Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancers.
Maemura K; Mataki Y; Kurahara H; Kawasaki Y; Iino S; Sakoda M; Uchikado Y; Arigami T; Uenosono Y; Mori S; Ueno S; Shinchi H; Natsugoe S
Anticancer Res; 2017 Jan; 37(1):233-237. PubMed ID: 28011497
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer.
Eguchi H; Nagano H; Kobayashi S; Kawamoto K; Wada H; Hama N; Tomimaru Y; Akita H; Sakai D; Satoh T; Kudo T; Isohashi F; Mori M; Doki Y
Cancer Chemother Pharmacol; 2014 Feb; 73(2):309-15. PubMed ID: 24258457
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01).
Hayashi T; Nakamura T; Kimura Y; Yoshida M; Someya M; Kawakami H; Sakuhara Y; Katoh N; Takahashi K; Ambo Y; Miura K; Motoya M; Tanaka E; Murakawa K; Yamabuki T; Yamazaki H; Katanuma A; Hirano S;
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):606-617. PubMed ID: 31306735
[TBL] [Abstract][Full Text] [Related]
13. S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure.
Todaka A; Fukutomi A; Boku N; Onozawa Y; Hironaka S; Yasui H; Yamazaki K; Taku K; Machida N; Sakamoto T; Tomita H
Jpn J Clin Oncol; 2010 Jun; 40(6):567-72. PubMed ID: 20189975
[TBL] [Abstract][Full Text] [Related]
14. Predictors of Poor Pathological Response to Neoadjuvant Gemcitabine Plus S-1 Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma.
Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
Pancreas; 2021 May-Jun 01; 50(5):744-750. PubMed ID: 34016892
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Ueno M; Okusaka T; Omuro Y; Isayama H; Fukutomi A; Ikeda M; Mizuno N; Fukuzawa K; Furukawa M; Iguchi H; Sugimori K; Furuse J; Shimada K; Ioka T; Nakamori S; Baba H; Komatsu Y; Takeuchi M; Hyodo I; Boku N
Ann Oncol; 2016 Mar; 27(3):502-8. PubMed ID: 26681680
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer.
Uwagawa T; Sakamoto T; Abe K; Okui N; Hata D; Shiba H; Futagawa Y; Aiba K; Yanaga K
Cancer Chemother Pharmacol; 2015 Jan; 75(1):191-6. PubMed ID: 25422155
[TBL] [Abstract][Full Text] [Related]
17. Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer.
Kawashima H; Itoh A; Ohno E; Nakamura M; Miyahara R; Ohmiya N; Hara K; Kanamori A; Itoh T; Taki T; Hirai T; Hashimoto S; Takeda K; Goto H; Hirooka Y
Cancer Chemother Pharmacol; 2011 Sep; 68(3):677-83. PubMed ID: 21132496
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial: study design and rationale of a phase II clinical trial.
Zhu X; Ju X; Cao F; Fang F; Qing S; Shen Y; Jia Z; Cao Y; Zhang H
BMJ Open; 2016 Dec; 6(12):e013220. PubMed ID: 27909037
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
Nagakawa Y; Hosokawa Y; Nakayama H; Sahara Y; Takishita C; Nakajima T; Hijikata Y; Kasuya K; Katsumata K; Tokuuye K; Tsuchida A
Cancer Chemother Pharmacol; 2017 May; 79(5):951-957. PubMed ID: 28378027
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.
Kim HS; Kim HY; Zang DY; Oh HS; Jeon JY; Cho JW; Park CK; Kim JH; Kim MJ; Ha HI; Kim JH; Han B; Song H; Kwon JH; Choi DR; Jung JY
Cancer Chemother Pharmacol; 2015 Apr; 75(4):711-8. PubMed ID: 25630414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]